Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)

Funding Opportunity PAR-16-129 from the NIH Guide for Grants and Contracts. The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests new research applications for Cooperative Agreement Research Projects (U01s) seeking support for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies must result in the identification of at least one lead compound ready for advanced therapeutic development. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding